Patents by Inventor Tobias Wunberg

Tobias Wunberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8916548
    Abstract: The present invention encompasses compounds of general Formula (1) wherein R1 to R4 are defined as in claim 1, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.
    Type: Grant
    Filed: July 28, 2009
    Date of Patent: December 23, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Tobias Wunberg, Ralph Brueckner, Dirk Kessler, Oliver Kraemer, Darryl McConnell, Siegfried Schneider, Lars van der Veen
  • Publication number: 20140073621
    Abstract: The present invention encompasses compounds of general formula (1) wherein R1 to R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.
    Type: Application
    Filed: November 22, 2013
    Publication date: March 13, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Siegfried SCHNEIDER, Dirk KESSLER, Lars van der VEEN, Tobias WUNBERG
  • Patent number: 8653097
    Abstract: The present invention encompasses compounds of general formula (1) wherein R1 to R4, A, X, m and k are defined as in claim 1, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.
    Type: Grant
    Filed: October 15, 2009
    Date of Patent: February 18, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Lars Van Der Veen, Darryl McConnell, Tobias Wunberg
  • Patent number: 8633183
    Abstract: The present invention encompasses compounds of general formula (1) wherein R1 to R3 are defined as in claim 1, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.
    Type: Grant
    Filed: January 24, 2011
    Date of Patent: January 21, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Siegfried Schneider, Dirk Kessler, Lars van der Veen, Tobias Wunberg
  • Patent number: 8618111
    Abstract: The present invention encompasses compounds of general formula (1) wherein R1 to R4R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.
    Type: Grant
    Filed: January 24, 2011
    Date of Patent: December 31, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Siegfried Schneider, Dirk Kessler, Lars van der Veen, Tobias Wunberg
  • Patent number: 8598157
    Abstract: 5-alkynyl-pyridine of general formula (I) their use as inhibitors of the activity of PI3Kalpha, pharmaceutical compositions containing them, and their use as a medicaments for the treatment and/or prevention of diseases characterized by excessive or abnormal cell proliferation and associated conditions such as cancer. The groups R1 to R6 and n have the meanings given in the claims and in the specification.
    Type: Grant
    Filed: January 24, 2012
    Date of Patent: December 3, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Tobias Wunberg, Oliver Kraemer, Lars van der Veer
  • Patent number: 8513255
    Abstract: The invention relates to substituted dihydroquinazolines and to processes for their preparation and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for use as antiviral agents, in particular against cytomegalo viruses.
    Type: Grant
    Filed: March 26, 2007
    Date of Patent: August 20, 2013
    Assignee: AiCuris GmbH + Co. KG.
    Inventors: Tobias Wunberg, Judith Baumeister, Ulrich Betz, Mario Jeske, Thomas Lampe, Susanne Nikolic, Juergen Reefschlaeger, Rudolf Schohe-Loop, Frank Suessmeier, Holger Zimmermann, Rolf Grosser, Kerstin Henninger, Guy Hewlett, Joerg Keldenich, Dieter Lang, Peter Nell
  • Publication number: 20130196975
    Abstract: The present invention encompasses compounds of general formula (1) wherein R1 to R4, m and n are defined as in the specification, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.
    Type: Application
    Filed: March 12, 2013
    Publication date: August 1, 2013
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Tobias WUNBERG, Siegfried SCHNEIDER, Lars VAN DER VEEN
  • Publication number: 20130165439
    Abstract: The present invention encompasses compounds of general formula (I) wherein the groups R1 to R5 are defined as in claim 1, which are suitable for treating diseases characterised by excessive or abnormal cell proliferation, and their use for preparing a medicament having the above-mentioned properties.
    Type: Application
    Filed: February 25, 2013
    Publication date: June 27, 2013
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Darryl MCCONNELL, Lars van der VEEN, Tobias WUNBERG
  • Patent number: 8466162
    Abstract: 5-alkynyl-pyridine of general formula (I) which are inhibitors of the activity of PI3K alpha, and their use in the treatment of diseases characterized by excessive or abnormal cell proliferation, such as cancer.
    Type: Grant
    Filed: January 24, 2012
    Date of Patent: June 18, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Tobias Wunberg, Oliver Kraemer, Lars Van Der Veen
  • Publication number: 20130023533
    Abstract: 5-alkynyl-pyridine of general formula (I) which are inhibitors of the activity of PI3K alpha, and their use in the treatment of diseases characterized by excessive or abnormal cell proliferation, such as cancer.
    Type: Application
    Filed: January 24, 2012
    Publication date: January 24, 2013
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Tobias WUNBERG, Oliver KRAEMER, Lars van der VEEN
  • Publication number: 20130023519
    Abstract: 5-alkynyl-pyridine of general formula (I) their use as inhibitors of the activity of PI3Kalpha, pharmaceutical compositions containing them, and their use as a medicaments for the treatment and/or prevention of diseases characterized by excessive or abnormal cell proliferation and associated conditions such as cancer. The groups R1 to R6 and n have the meanings given in the claims and in the specification.
    Type: Application
    Filed: January 24, 2012
    Publication date: January 24, 2013
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Tobias WUNBERG, Oliver KRAEMER, Lars van der VEEN
  • Patent number: 8343981
    Abstract: The invention relates to heterocyclyl-substituted dihydroquinazolines of formula (I), to processes for their preparation, to medicaments containing them, and to methods for the treatment and/or prophylaxis of diseases, in particular, for use as anti-viral agents, in particular, against cytomegaloviruses.
    Type: Grant
    Filed: April 28, 2004
    Date of Patent: January 1, 2013
    Assignee: AiCuris GmbH & Co. KG
    Inventors: Tobias Wunberg, Judith Baumeister, Mario Jeske, Peter Nell, Susanne Nikolic, Frank Suessmeier, Holger Zimmermann, Rolf Grosser, Kerstin Henninger, Guy Hewlett, Joerg Keldenich, Dieter Lang
  • Patent number: 8318761
    Abstract: The invention relates to substituted arylsulfonamides of formula (I) and methods for their preparation as well as their use for the production of medicaments for the treatment and/or prophylaxis of diseases, especially for use as antiviral agents, particularly against cytomegaloviruses.
    Type: Grant
    Filed: September 3, 2008
    Date of Patent: November 27, 2012
    Assignee: Aicuris GmbH & Co. KG
    Inventors: Niels Svenstrup, Holger Zimmermann, Dagmar Karthaus, Andreas Goeller, Dirk Heimbach, Kerstin Henninger, Dieter Lang, Daniela Paulsen, Bernd Riedl, Rudolf Schohe-Loop, Joachim Schuhmacher, Tobias Wunberg
  • Patent number: 8314113
    Abstract: The invention relates to substituted dihydroquinazolines and to a method for the production thereof, the use thereof for treating and/or preventing diseases and for producing drugs for treating and/or preventing diseases, in particular for the use of the inventive dihydroquinazolines in the form of antiviral agents, in particular against cytomegaloviruses.
    Type: Grant
    Filed: October 28, 2004
    Date of Patent: November 20, 2012
    Assignee: Aicuris GmbH & Co. KG
    Inventors: Tobias Wunberg, Judith Baumeister, Mario Jeske, Peter Nell, Susanne Nikolic, Frank Suessmeier, Holger Zimmermann, Rolf Grosser, Guy Hewlett, Jorg Keldenich, Dieter Lang, Kerstin Henninger
  • Patent number: 8304556
    Abstract: The present invention encompasses compounds of general formula (1) wherein R1 to R3 are defined as in claim 1, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.
    Type: Grant
    Filed: January 11, 2012
    Date of Patent: November 6, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Darryl McConnell, Maria Impagnatiello, Dirk Kessler, Oliver Kraemer, Siegfried Schneider, Lars Van Der Veen, Ulrike Weyer-Czernilofsky, Tobias Wunberg
  • Patent number: 8288379
    Abstract: The present invention encompasses compounds of general formula (1) wherein R1 to R3 and X are defined as in claim 1, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.
    Type: Grant
    Filed: April 20, 2010
    Date of Patent: October 16, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Lars Van Der Veen, Maria Impagnatiello, Darryl McConnell, Siegfried Schneider, Tobias Wunberg
  • Patent number: 8263624
    Abstract: The invention relates to aryl-substituted heterocycles, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of thromboembolic disorders.
    Type: Grant
    Filed: May 25, 2007
    Date of Patent: September 11, 2012
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Michael Härter, Tobias Wunberg, Swen Allerheiligen, Marcus Bauser, Ulrich Rester, Stefan Heitmeier
  • Patent number: 8198282
    Abstract: This invention relates to substituted azaquinazolines, to a process for their preparation, to pharmaceutical compositions containing them, and to their use for the treatment and/or prophylaxis of diseases, especially for use as antiviral agents, in particular against cytomegaloviruses.
    Type: Grant
    Filed: December 24, 2009
    Date of Patent: June 12, 2012
    Assignee: Aicuris GmbH & Co. KG
    Inventors: Tobias Wunberg, Judith Baumeister, Mario Jeske, Frank Suessmeier, Holger Zimmermann, Kerstin Henninger, Dieter Lang
  • Publication number: 20120108618
    Abstract: The present invention encompasses compounds of general formula (1) wherein R1 to R3 and X are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.
    Type: Application
    Filed: April 22, 2010
    Publication date: May 3, 2012
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Lars Van Der Veen, Darryl Mcconnell, Siegfried Schneider, Matthias Grauert, Andreas Schoop, Tobias Wunberg